A recurrence‐predictive model based on eight genes and tumor mutational burden/microsatellite instability status in Stage II/III colorectal cancer

• Published in: Cancer medicine (Malden, MA) MA), 2024-01, Vol.13 (1), p.e6720-n/a
• Main Authors: Gao, Zhaoya, Wan, Zhiyi, Yu, Pengfei, Shang, Yan, Zhu, Guangsheng, Jiang, Huiyuan, Chen, Yawei, Wang, Shengzhou, Lei, Fuming, Huang, Wensheng, Zeng, Qingmin, Wang, Yanzhao, Rong, Wanshui, Hong, Yuming, Gao, Qingkun, Niu, Pengfei, Zhai, Zhichao, An, Ke, Ding, Changmin, Wang, Yunfan, Gu, Guoli, Wang, Xin, Meng, Qingkai, Ye, Shengwei, Liu, Haiyi, Gu, Jin
• Format: Article
• Language: English
• Subjects: Biomarkers; Chemotherapy; Colorectal cancer; Colorectal carcinoma; Doublecortin protein; Gene expression; Genetic factors; Immunotherapy; Medical prognosis; Microsatellite instability; Mutation; Patients; Prediction models; predictive model; recurrence risk; recurrence‐free survival; Statistical analysis; Surgery; Survival analysis; Tumors; whole‐exome sequencing
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.6720

Background Although adjuvant chemotherapy (ACT) is widely used to treat patients with Stage II/III colorectal cancer (CRC), administering ACT to specific patients remains a challenge. The decision to ACT requires an accurate assessment of recurrence risk and absolute treatment benefit. However, the traditional TNM staging system does not accurately assess a patient's individual risk of recurrence. Methods To identify recurrence risk‐related genetic factors for Stage II/III CRC patients after radical surgery, we conducted an analysis of whole‐exome sequencing of 47 patients with Stage II/III CRC who underwent radical surgery at five institutions. Patients were grouped into non‐recurrence group (NR, n = 24, recurrence‐free survival [RFS] > 5 years) and recurrence group (R, n = 23, RFS